Atish Dipankar Choudhury, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 25 | 2024 | 11229 | 1.610 |
Why?
|
Radium | 2 | 2024 | 70 | 1.080 |
Why?
|
Chromones | 1 | 2022 | 148 | 0.800 |
Why?
|
Prostate-Specific Antigen | 9 | 2024 | 2487 | 0.620 |
Why?
|
Aniline Compounds | 1 | 2022 | 1094 | 0.540 |
Why?
|
Antineoplastic Agents, Hormonal | 4 | 2023 | 1535 | 0.530 |
Why?
|
Retinoblastoma | 1 | 2019 | 321 | 0.530 |
Why?
|
Bone Neoplasms | 3 | 2024 | 2565 | 0.530 |
Why?
|
Immunoconjugates | 1 | 2023 | 976 | 0.510 |
Why?
|
Neoplasms, Hormone-Dependent | 2 | 2014 | 410 | 0.430 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2022 | 2884 | 0.420 |
Why?
|
Androgen Antagonists | 4 | 2024 | 1421 | 0.370 |
Why?
|
Androgen Receptor Antagonists | 2 | 2023 | 125 | 0.350 |
Why?
|
Adenocarcinoma | 2 | 2021 | 6401 | 0.330 |
Why?
|
Antineoplastic Agents | 6 | 2023 | 13699 | 0.330 |
Why?
|
Prednisone | 3 | 2024 | 1567 | 0.310 |
Why?
|
Urogenital Neoplasms | 2 | 2020 | 132 | 0.310 |
Why?
|
Hormones | 2 | 2023 | 871 | 0.300 |
Why?
|
Prostatectomy | 5 | 2024 | 1841 | 0.290 |
Why?
|
PTEN Phosphohydrolase | 3 | 2022 | 1120 | 0.260 |
Why?
|
Immunotherapy | 2 | 2020 | 4755 | 0.260 |
Why?
|
Male | 42 | 2024 | 365249 | 0.250 |
Why?
|
Neoplasms | 3 | 2023 | 22390 | 0.240 |
Why?
|
Receptors, Androgen | 3 | 2020 | 1091 | 0.240 |
Why?
|
Ubiquitin-Protein Ligases | 3 | 2018 | 1903 | 0.230 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2023 | 5342 | 0.220 |
Why?
|
Leuprolide | 2 | 2024 | 313 | 0.210 |
Why?
|
BRCA1 Protein | 3 | 2023 | 1156 | 0.210 |
Why?
|
High-Throughput Nucleotide Sequencing | 5 | 2024 | 3671 | 0.200 |
Why?
|
Humans | 51 | 2024 | 768887 | 0.190 |
Why?
|
Tissue Extracts | 1 | 2022 | 139 | 0.190 |
Why?
|
Cysteine Endopeptidases | 1 | 2004 | 542 | 0.190 |
Why?
|
Thiohydantoins | 1 | 2021 | 19 | 0.190 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2024 | 249 | 0.190 |
Why?
|
Multienzyme Complexes | 1 | 2004 | 665 | 0.180 |
Why?
|
Neoplasm Metastasis | 4 | 2018 | 4926 | 0.180 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 11886 | 0.170 |
Why?
|
Ubiquitin | 2 | 2005 | 843 | 0.170 |
Why?
|
Cyclic AMP Response Element-Binding Protein A | 1 | 2019 | 21 | 0.170 |
Why?
|
Camptothecin | 1 | 2023 | 600 | 0.170 |
Why?
|
Genetic Counseling | 1 | 2023 | 634 | 0.160 |
Why?
|
Cell Cycle | 2 | 2005 | 2937 | 0.160 |
Why?
|
Genes, Retinoblastoma | 1 | 2019 | 125 | 0.160 |
Why?
|
DNA Repair | 3 | 2023 | 2054 | 0.160 |
Why?
|
Administration, Cutaneous | 1 | 2021 | 716 | 0.160 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2018 | 101 | 0.150 |
Why?
|
Medical Oncology | 2 | 2020 | 2350 | 0.150 |
Why?
|
Tumor Suppressor Proteins | 2 | 2005 | 2813 | 0.150 |
Why?
|
Neutropenia | 1 | 2023 | 893 | 0.140 |
Why?
|
Androgens | 2 | 2024 | 1285 | 0.140 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2014 | 957 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2020 | 567 | 0.130 |
Why?
|
Urologic Neoplasms | 1 | 2019 | 318 | 0.130 |
Why?
|
Estrogen Receptor alpha | 1 | 2020 | 581 | 0.130 |
Why?
|
Retinoblastoma Protein | 1 | 2019 | 673 | 0.120 |
Why?
|
Alkaline Phosphatase | 1 | 2018 | 864 | 0.120 |
Why?
|
Neoplasm, Residual | 1 | 2020 | 1019 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2022 | 2460 | 0.120 |
Why?
|
Anoikis | 1 | 2014 | 49 | 0.110 |
Why?
|
Radiosurgery | 1 | 2023 | 1346 | 0.110 |
Why?
|
Estrogens | 1 | 2021 | 1537 | 0.110 |
Why?
|
Germ-Line Mutation | 1 | 2022 | 1887 | 0.110 |
Why?
|
Video Recording | 1 | 2019 | 976 | 0.110 |
Why?
|
Estradiol | 1 | 2021 | 1952 | 0.110 |
Why?
|
Immunoblotting | 1 | 2016 | 1647 | 0.110 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2022 | 2063 | 0.110 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2024 | 9442 | 0.110 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2024 | 4651 | 0.100 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2019 | 798 | 0.100 |
Why?
|
Hemoglobins | 1 | 2018 | 1531 | 0.100 |
Why?
|
Treatment Outcome | 6 | 2024 | 65485 | 0.100 |
Why?
|
DNA, Neoplasm | 1 | 2017 | 1748 | 0.100 |
Why?
|
Insulin Resistance | 1 | 2024 | 3982 | 0.090 |
Why?
|
DNA Methylation | 1 | 2024 | 4432 | 0.080 |
Why?
|
Mitosis | 2 | 2005 | 1181 | 0.080 |
Why?
|
Forkhead Transcription Factors | 1 | 2016 | 1625 | 0.080 |
Why?
|
Taxoids | 1 | 2012 | 668 | 0.080 |
Why?
|
Survival Analysis | 2 | 2018 | 10115 | 0.080 |
Why?
|
DNA Copy Number Variations | 1 | 2018 | 2055 | 0.080 |
Why?
|
HeLa Cells | 2 | 2005 | 3076 | 0.080 |
Why?
|
Sarcoma | 1 | 2019 | 1806 | 0.080 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2012 | 878 | 0.080 |
Why?
|
Phenylthiohydantoin | 2 | 2020 | 215 | 0.080 |
Why?
|
Nanotechnology | 1 | 2014 | 714 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2018 | 2960 | 0.070 |
Why?
|
G2 Phase | 2 | 2005 | 135 | 0.070 |
Why?
|
Middle Aged | 13 | 2024 | 223740 | 0.070 |
Why?
|
Prospective Studies | 6 | 2024 | 54950 | 0.070 |
Why?
|
Immunohistochemistry | 2 | 2019 | 11119 | 0.070 |
Why?
|
Cell Line | 4 | 2022 | 15603 | 0.070 |
Why?
|
Transfection | 2 | 2005 | 5763 | 0.070 |
Why?
|
Gene Expression Regulation | 1 | 2004 | 11934 | 0.070 |
Why?
|
Genetic Markers | 1 | 2012 | 2604 | 0.060 |
Why?
|
Registries | 1 | 2022 | 8384 | 0.060 |
Why?
|
Prostate | 2 | 2023 | 1781 | 0.060 |
Why?
|
Prognosis | 5 | 2020 | 30044 | 0.060 |
Why?
|
Aged, 80 and over | 4 | 2024 | 59738 | 0.060 |
Why?
|
Multivariate Analysis | 1 | 2018 | 12093 | 0.060 |
Why?
|
Nitriles | 2 | 2020 | 990 | 0.060 |
Why?
|
DNA Damage | 3 | 2020 | 2472 | 0.060 |
Why?
|
Nocodazole | 1 | 2004 | 95 | 0.060 |
Why?
|
Aged | 9 | 2024 | 171790 | 0.060 |
Why?
|
Threonine | 1 | 2005 | 273 | 0.060 |
Why?
|
Serine | 2 | 2005 | 831 | 0.060 |
Why?
|
Mitomycin | 1 | 2005 | 262 | 0.060 |
Why?
|
Carcinoma, Renal Cell | 1 | 2019 | 3200 | 0.060 |
Why?
|
Benzamides | 2 | 2020 | 1387 | 0.060 |
Why?
|
Sulfites | 1 | 2024 | 83 | 0.060 |
Why?
|
Colorectal Neoplasms | 1 | 2024 | 6982 | 0.060 |
Why?
|
Quality of Life | 2 | 2023 | 13510 | 0.060 |
Why?
|
Urogenital System | 1 | 2023 | 88 | 0.050 |
Why?
|
Dimerization | 1 | 2005 | 886 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5434 | 0.050 |
Why?
|
DNA Mutational Analysis | 2 | 2017 | 4123 | 0.050 |
Why?
|
Plasmids | 2 | 2005 | 2269 | 0.050 |
Why?
|
Lutetium | 1 | 2023 | 38 | 0.050 |
Why?
|
S Phase | 1 | 2004 | 424 | 0.050 |
Why?
|
G1 Phase | 1 | 2004 | 403 | 0.050 |
Why?
|
Kidney Neoplasms | 1 | 2019 | 4300 | 0.050 |
Why?
|
Heterocyclic Compounds, 1-Ring | 1 | 2023 | 68 | 0.050 |
Why?
|
Immunoprecipitation | 1 | 2005 | 874 | 0.050 |
Why?
|
Mutation | 7 | 2022 | 30266 | 0.050 |
Why?
|
Radiopharmaceuticals | 1 | 2012 | 2734 | 0.050 |
Why?
|
Macromolecular Substances | 1 | 2005 | 1435 | 0.050 |
Why?
|
Brain Neoplasms | 1 | 2024 | 9213 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2023 | 8664 | 0.050 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2023 | 277 | 0.050 |
Why?
|
Cross-Linking Reagents | 1 | 2005 | 692 | 0.050 |
Why?
|
Sequence Analysis, DNA | 2 | 2024 | 4784 | 0.050 |
Why?
|
Sequence Analysis | 1 | 2022 | 240 | 0.050 |
Why?
|
Neoplasm Proteins | 1 | 2014 | 3608 | 0.050 |
Why?
|
Credentialing | 1 | 2022 | 114 | 0.050 |
Why?
|
Cell Line, Tumor | 2 | 2016 | 17174 | 0.050 |
Why?
|
Molecular Targeted Therapy | 1 | 2012 | 2830 | 0.050 |
Why?
|
Dipeptides | 1 | 2023 | 386 | 0.050 |
Why?
|
Neoplasm Staging | 3 | 2020 | 11262 | 0.040 |
Why?
|
Protease Inhibitors | 1 | 2004 | 752 | 0.040 |
Why?
|
Signal Transduction | 2 | 2022 | 23652 | 0.040 |
Why?
|
Genes, BRCA2 | 1 | 2023 | 593 | 0.040 |
Why?
|
RNA, Double-Stranded | 1 | 2021 | 292 | 0.040 |
Why?
|
Cell Separation | 1 | 2005 | 1728 | 0.040 |
Why?
|
Nucleosomes | 1 | 2023 | 492 | 0.040 |
Why?
|
Preoperative Period | 1 | 2021 | 565 | 0.040 |
Why?
|
BRCA2 Protein | 1 | 2023 | 803 | 0.040 |
Why?
|
Combined Modality Therapy | 2 | 2021 | 8559 | 0.040 |
Why?
|
Germ Cells | 1 | 2022 | 644 | 0.040 |
Why?
|
Mice | 3 | 2016 | 82074 | 0.040 |
Why?
|
Protein Kinases | 1 | 2005 | 1611 | 0.040 |
Why?
|
Mass Spectrometry | 1 | 2005 | 2204 | 0.040 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2004 | 1320 | 0.040 |
Why?
|
Cell Division | 1 | 2005 | 4478 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2019 | 793 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2022 | 13593 | 0.040 |
Why?
|
Chromosomes, Human, Pair 18 | 1 | 2018 | 247 | 0.040 |
Why?
|
Phosphorylation | 2 | 2005 | 8317 | 0.030 |
Why?
|
Interferons | 1 | 2021 | 720 | 0.030 |
Why?
|
Gene Duplication | 1 | 2018 | 315 | 0.030 |
Why?
|
Genes, myc | 1 | 2018 | 391 | 0.030 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2018 | 350 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2004 | 6131 | 0.030 |
Why?
|
Kinetics | 1 | 2004 | 6334 | 0.030 |
Why?
|
Open Reading Frames | 1 | 2019 | 818 | 0.030 |
Why?
|
Breast Neoplasms | 3 | 2020 | 21187 | 0.030 |
Why?
|
Survival Rate | 2 | 2020 | 12873 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2005 | 6085 | 0.030 |
Why?
|
Recombinant Fusion Proteins | 1 | 2004 | 3744 | 0.030 |
Why?
|
Genetic Vectors | 1 | 2005 | 3414 | 0.030 |
Why?
|
Anilides | 1 | 2018 | 414 | 0.030 |
Why?
|
Rare Diseases | 1 | 2020 | 630 | 0.030 |
Why?
|
Disease Progression | 1 | 2012 | 13677 | 0.030 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2018 | 664 | 0.030 |
Why?
|
Body Composition | 1 | 2024 | 2461 | 0.030 |
Why?
|
Flow Cytometry | 1 | 2005 | 5905 | 0.030 |
Why?
|
Genes, Tumor Suppressor | 1 | 2018 | 1064 | 0.030 |
Why?
|
Follow-Up Studies | 3 | 2020 | 39394 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2022 | 3811 | 0.030 |
Why?
|
Animals | 3 | 2016 | 169408 | 0.030 |
Why?
|
Gene Dosage | 1 | 2017 | 1222 | 0.030 |
Why?
|
Peptides | 1 | 2005 | 4353 | 0.030 |
Why?
|
Gene Rearrangement | 1 | 2018 | 1148 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2005 | 10778 | 0.030 |
Why?
|
Testosterone | 1 | 2024 | 2494 | 0.030 |
Why?
|
Protein Binding | 1 | 2005 | 9344 | 0.030 |
Why?
|
Genome-Wide Association Study | 1 | 2012 | 12798 | 0.030 |
Why?
|
Phenotype | 2 | 2023 | 16735 | 0.030 |
Why?
|
Cerebral Hemorrhage | 1 | 2023 | 2660 | 0.020 |
Why?
|
Haplotypes | 1 | 2018 | 2725 | 0.020 |
Why?
|
Genome | 1 | 2020 | 1752 | 0.020 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2004 | 2250 | 0.020 |
Why?
|
Enhancer Elements, Genetic | 1 | 2018 | 1369 | 0.020 |
Why?
|
Fluorescence Resonance Energy Transfer | 1 | 2014 | 414 | 0.020 |
Why?
|
DNA | 1 | 2005 | 7214 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 1780 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 6320 | 0.020 |
Why?
|
Alleles | 1 | 2022 | 6901 | 0.020 |
Why?
|
Genotype | 1 | 2005 | 13048 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2017 | 2001 | 0.020 |
Why?
|
Risk Assessment | 2 | 2021 | 24330 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2004 | 12809 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2018 | 2167 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2024 | 4980 | 0.020 |
Why?
|
Genetic Loci | 1 | 2018 | 2630 | 0.020 |
Why?
|
Liver | 1 | 2024 | 7579 | 0.020 |
Why?
|
Societies, Medical | 1 | 2020 | 3967 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2019 | 5801 | 0.020 |
Why?
|
Female | 7 | 2020 | 397464 | 0.020 |
Why?
|
Neutrophils | 1 | 2019 | 3785 | 0.020 |
Why?
|
Internet | 1 | 2019 | 3112 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2014 | 2635 | 0.020 |
Why?
|
Time Factors | 2 | 2005 | 40266 | 0.020 |
Why?
|
Genomics | 1 | 2022 | 5928 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2023 | 14795 | 0.020 |
Why?
|
Pyridines | 1 | 2018 | 2896 | 0.020 |
Why?
|
Adult | 4 | 2020 | 223818 | 0.010 |
Why?
|
Radiation, Ionizing | 1 | 2005 | 252 | 0.010 |
Why?
|
Cell Survival | 1 | 2014 | 5794 | 0.010 |
Why?
|
United States | 2 | 2023 | 73180 | 0.010 |
Why?
|
Software | 1 | 2017 | 4480 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7460 | 0.010 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2005 | 414 | 0.010 |
Why?
|
Growth Substances | 1 | 2005 | 760 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 5707 | 0.010 |
Why?
|
Cytoplasm | 1 | 2005 | 1505 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2020 | 81892 | 0.010 |
Why?
|
Embryo, Mammalian | 1 | 2005 | 1676 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 18065 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2023 | 36861 | 0.010 |
Why?
|
Models, Genetic | 1 | 2005 | 3446 | 0.010 |
Why?
|
Young Adult | 1 | 2019 | 60110 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2005 | 4528 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2005 | 9564 | 0.010 |
Why?
|
Stem Cells | 1 | 2005 | 3540 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2005 | 14485 | 0.010 |
Why?
|
Models, Biological | 1 | 2005 | 9499 | 0.000 |
Why?
|